ArticleFrontiers in medicine2026
Evolution of idiopathic membranous nephropathy to class v lupus nephritis: a case report and literature review.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An unusual presentation of membranous nephropathy with primary and secondary features: a case report.BMC nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The M-type phospholipase A2 receptor (PLA2R) antibody positivity is considered a specific serological marker for idiopathic membranous nephropathy (IMN), and its presence in class V lupus nephritis (LN) is rare. There is limited reporting on the longitudinal progression from IMN to systemic lupus erythematosus (SLE) with class V LN, particularly in cases with persistently positive anti-PLA2R antibodies. Case presentation: A 54-year-old woman presented with nephrotic syndrome in 2016, with initial renal biopsy showing podocyte disease. In 2020, disease recurrence with positive serum anti-PLA2R antibodies led to a second biopsy diagnosing IMN stage II. In 2024, she presented with edema and facial erythema. Serology revealed new-onset positive ANA and anti-dsDNA antibodies alongside persistent anti-PLA2R positivity, meeting SLE criteria. A third renal biopsy confirmed class V LN. After treatment with methylprednisolone and hydroxychloroquine, and following a rituximab infusion reaction, she achieved clinical remission with obinutuzumab. Conclusion: This case highlights that positive anti-PLA2R antibodies do not definitively exclude secondary MN such as class V LN. Long-term serological monitoring and repeat renal biopsy should be considered in IMN patients with atypical clinical evolution to identify potential transformation to LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.